Internal Medicine
RSSArticles
-
CVD Risk from Ketogenic Diets
A recent analysis of the UK Biobank data found that subjects on a low-carbohydrate, high-fat diet had higher levels of low-density lipoprotein cholesterol and apolipoprotein B, and an increase in incident major adverse cardiovascular events over a 12-year follow-up than subjects on a standard diet.
-
Comparing Antidepressants’ Effects on Weight Gain
This observational study finds that, compared to sertraline, six-month weight gain is higher in patients prescribed other antidepressants in the same category (paroxetine, citalopram, escitalopram) as well as in patients prescribed duloxetine and venlafaxine, similar in patients prescribed fluoxetine, and lower in patients prescribed bupropion.
-
Elafibranor Tablets (Iqirvo)
The U.S. Food and Drug Administration has approved an oral dual peroxisome proliferator-activated alpha and delta receptor agonist for the treatment of primary biliary cholangitis, formerly known as primary biliary cirrhosis. Elafibranor was granted an accelerated approval and an orphan designation.
-
Racial Inequities in Shared Decision-Making for Critically Ill Patients
In this thematic analysis of a previously conducted randomized clinical trial, disparate shared decision-making behaviors were observed among meetings with white vs. Black caregivers of critically ill patients, illustrating opportunities for future clinician-level interventions.
-
Is Artificial Intelligence Coming for Your Job?
A retrospective analysis of plain chest X-ray images in the medical record using deep learning in patients suitable for risk assessment for atherosclerotic cardiovascular disease (ASCVD) has shown similar results as the American College of Cardiology/American Heart Association ASCVD risk calculator for determining who is at sufficient risk to consider statin therapy.
-
Empagliflozin Post-Acute Myocardial Infarction
A prespecified further analysis of the EMPACT-MI trial has shown that patients within two weeks of an acute myocardial infarction who are at risk for heart failure who receive empagliflozin compared to placebo have significantly fewer episodes of heart failure hospitalizations over a median follow-up of 18 months.
-
How Do the Rhythm and 12-Lead Go Together?
The patient whose electrocardiogram (ECG) is shown presented for care because of chest pain. Looking at this ECG, can you determine why?
-
Imetelstat Injection (Rytelo)
The U.S. Food and Drug Administration has approved a first-in-class telomerase inhibitor for the treatment of myelodysplastic syndrome with transfusion-dependent anemia.
-
Summer Travel: News Clinicians (and Their Patients) Can Use
The pandemic has waned. Summer vacation has arrived. Airports are crowded. Planes are full. New science can guide us as we and our patients travel this season.
-
Pivmecillinam Tablets (Pivya)
The U.S. Food and Drug Administration (FDA) has approved a new antibacterial for the treatment of uncomplicated urinary tract infection (UTI) in female adults.